To my untrained eye, the following appears like competition for BTRN. Any trained opinions?
Isotechnika Inc. to present trial results of its lead drug ISA(TX)247 at International medical/scientific meetings
Pre-clinical and Phase 1 human clinical trial results to be presented at
several key International conferences
www.isotechnika.com
Toronto Stock Exchange: ISA
EDMONTON, AB, April 23 /CNW/ - Isotechnika Inc., a innovative life
sciences company specializing in the research and development of novel
immunosuppressive drugs for prevention of organ rejection after
transplantation and for the treatment of autoimmune diseases such as
psoriasis, rheumatoid arthritis and type 1 diabetes, today announced that the
Company has been invited to present papers detailing the results for its
immunosuppressive drug ISA(TX)247 at several key Medical Scientific/Meetings
over the next several months.
The Company will present:
- One paper at the International Society for Heart and Lung
Transplantation Meeting to be held in Vancouver Canada from April 25-
28, 2001.
- Five papers including one symposium presentation at the American
Society for Transplantation Meeting to be held in Chicago May 12-16,
2001.
- Five papers including one symposium presentation at the International
Congress of Therapeutic Drug Monitoring and Clinical Toxicology to be
held in Washington D.C. September 1-6,2001.
"All the submitted papers underwent detailed scientific peer review prior
to acceptance. With an acceptance rate of less than 20% for some of the
meetings, the fact that all the submitted papers were accepted for
presentation lends support to the quality of the data obtained for
ISA(TX)247." said Dr. Randall Yatscoff, President of Isotechnika. "An
important scientific milestone for a new drug is to obtain acceptance of the
data by peers. We feel that this has been achieved; moreover, this high
acceptance rate further supports the continued work performed by our
scientific team."
The Company's lead drug, ISA(TX)247, is a novel immunosuppressive drug
designed for the prevention of organ rejection after transplantation, and for
treatment of autoimmune diseases such as arthritis and psoriasis. Pre-clinical
and Phase 1 studies in humans for ISA(TX)247 have revealed superior efficacy
and reduced toxicity when compared with current gold standard medications such
as cyclosporine. Annual worldwide sales of cyclosporine exceed C$2 billion.
The applications to commence Phase II trials for the drug in renal
transplantation were recently filed with the Food and Drug Administration of
the United States and the Health Protection Branch of the Government of
Canada.
About Isotechnika
Isotechnika is a life-sciences company located in Edmonton. Its lead drug
is ISA(TX)247. Isotechnika also globally markets and distributes a breath test
diagnostic product line, which it has developed. One of these products, the
Helikit, is the gold standard for the diagnosis of ulcers. |
